RedHill Biopharma Ltd. (RDHL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RDHL currently has 50.9B outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 200.99% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 31, 2025 |
F-1 filing: This F-1 filing discusses the indemnification of directors and officers, insurance coverage, ordinary shares outstanding, and the offering of ADSs by a selling shareholder. |
51B | 0 |
| Sep 05, 2025 |
POS AM filing: This POS AM filing from 2025-09-05 relates to the offering of up to 424,000 ADSs representing 4,240,000,000 Ordinary Shares by selling shareholders. |
23B | 0 |
| Jun 25, 2025 |
F-1 filing: This F-1 filing describes the details of a USD $10 million equity line of credit established through the Any Market Purchase Agreement, including the potential issuance of up to 5,596,490 ADSs, and a Commitment Warrant for the Selling Shareholder to purchase up to 333,333 ADSs at $3.00 per ADS. |
23B | 0 |
| Apr 10, 2025 |
20-F filing | 12899.8M shares outstanding |
13B | 0 |
| Aug 09, 2024 |
F-3 filing: RedHill Biopharma Ltd. is offering American Depositary Shares, ordinary shares, warrants, subscription rights and/or units. The aggregate market value worldwide of our outstanding voting and non-voting common equity held by non-affiliates was approximately $24.2 million, based on 32,013,477 ADSs outstanding, of which 31,891,931 ADSs were held by non-affiliates, and a per ADS price of $0.76 based on the closing sale price of our ADSs on the Nasdaq Capital Market on August 1, 2024. |
13B | 0 |
| Apr 18, 2024 |
POS AM filing: This POS AM filing relates to the offering of up to 10,600,000 ADSs, representing 4,240,000,000 Ordinary Shares, by selling shareholders. |
13B | 0 |
| Apr 08, 2024 |
20-F filing | 12746.8M shares outstanding |
13B | 0 |
| Feb 09, 2024 |
F-1 filing: This F-1 filing relates to the resale of American Depositary Shares representing ordinary shares issued or issuable upon the exercise of warrants by selling shareholders. |
1.6B | 7.4B |
| Oct 13, 2023 |
F-3 filing: This F-3 filing relates to the resale by selling shareholders of up to 8,861,961 American Depositary Shares representing 3,544,784,400 Ordinary Shares issued or issuable upon the exercise of warrants. |
1.6B | 3.2B |
| Aug 04, 2023 |
F-3 filing: This F-3 filing relates to the resale by selling shareholders of up to 1,998,221 American Depositary Shares representing 799,288,400 Ordinary Shares issued or issuable upon the exercise of warrants. |
1.2B | 26M |
| Apr 28, 2023 |
20-F filing | 1179.7M shares outstanding |
1.2B | 0 |
| Mar 17, 2022 |
20-F filing | 526.8M shares outstanding |
530M | 0 |
| Jul 29, 2021 |
F-3 filing: RedHill Biopharma Ltd. is offering American Depositary Shares, ordinary shares, warrants, subscription rights, and/or units up to $200,000,000 via shelf registration and up to $100,000,000 worth of American Depositary Shares through an at-the-market offering with SVB Leerink and Cantor Fitzgerald & Co. as sales agents. |
380M | 22M |
| Mar 30, 2021 |
F-3 filing: RedHill Biopharma is offering 7,151,422 American Depositary Shares representing 71,514,220 Ordinary Shares via a shelf registration, allowing selling stockholders to resell their shares from time to time. |
380M | 7.2M |
| Mar 18, 2021 |
20-F filing | 384.0M shares outstanding |
380M | 0 |
| Mar 04, 2020 |
20-F filing | 352.7M shares outstanding |
350M | 0 |